An interventional study of Breathing Intervention in Depressive Disorder, Anxiety and Adolescent, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Mayo Clinic · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 319 studies in Depressive Disorder with a site in United States — 38 open to participants now, 44 under way, 2 of them phase 3. Depressive Disorder · United States.
Among the 319 studies in Depressive Disorder with a site in United States, this one is the 186th largest by planned enrollment of the 275 interventional ones that give a count, is one of 11 that started in 2026, is one of 127 with no phase, reaches primary completion later than 12 of the 43 other live ones, and was the 312th registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →38 of the 319 studies in Depressive Disorder with a site in United States are open now. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, Brazil and 12 more countries
Ages 18–75
Ksana Health · Sites in United States
Ages 13–24
University of California, San Diego · Sites in United States
Ages 18–65
Mayo Clinic · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
319 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 61 · Phase 3 41 · Phase 4 34
First in 1988; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 85 across the 275 interventional studies, 149 across the 40 observational. Of the 260 that completed or were terminated, 98 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 319 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
Mayo Clinic has 4 studies filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
16 of the studies in Depressive Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07841483Slingshot AIAI Mental Health Tool vs. Psychoeducation Control | 2026-12 |
| NCT06508450New York UniversityA Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults | 2026-12 |
| NCT05282277University of North Carolina, Chapel HillExamining the Effects of Estradiol on Neural and Molecular Response to Reward | 2026-12-31 |
| NCT05920252Ksana HealthA Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | 2026-12-31 |
| NCT05011864University of Texas at AustinIntegrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 319 studies in Depressive Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the feasibility of a structured breathing intervention in rural and non-rural adolescents diagnosed with anxiety and depression, recruited from outpatient pediatric and child/adolescent psychiatry clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rural and non-rural adolescent patients of Mayo Clinic Health Systems, aged 12 to 17 years, with a clinical diagnosis of mild to moderate anxiety and/or depression will follow a structured breathing practice (Seokmun Hoheup) at least 3 times per week.
Behavioral: Breathing Intervention
Participants will follow a structured breathing practice (Seokmun Hoheup) that progresses in incremental steps, beginning with 15 minutes, increasing to 30 minutes, and then to 36 minutes per session over the course of the program.
Feasibility of Intervention Measure (FIM) score
The Feasibility of Intervention Measure (FIM) is a self-reported questionnaire for participants to rate the feasibility of the breathing practice intervention on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)
Time frame: 4 months
Acceptability of Intervention Measure (AIM) score
The Acceptability of Intervention Measure (AIM) is a self-reported, 4 question survey, for participants to rate their acceptance of the breathing practice intervention on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)
Time frame: 4 months
Intervention Appropriateness Measure (IAM) score
The Intervention Appropriateness Measure (IAM) is a self-reported, 4 question survey, for participants to rate the appropriateness of the breathing practice intervention on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)
Time frame: 4 months
Recruitment feasibility
Proportion of eligible adolescents enrolled out of total participants screened
Time frame: 4 months
Retention feasibility
Proportion of participants retained through final assessment out of total enrolled
Time frame: 4 months
System Usability Scale (SUS) score
Digital usability will be assessed using the System Usability Scale (SUS) tool, a self-reported 10 question survey, for participants to rate the usability of the digital app platform on a 5-point Likert scale. Possible scores range from 0 (Completely Disagree) to 5 (Completely Agree)
Time frame: 4 months
Total number of log-ins
Total number of times participants logged into the digital app platform
Time frame: 4 months
Completion rate of assigned breathing practices
Adherence to breathing practice and intervention engagement will be assessed as the completion rate of assigned sessions as measured by the session attendance logs
Time frame: 4 months
Feasibility of collecting physiological data from baseline to 4 months
Feasibility will be assessed based on data completeness, participant tolerance, and procedural viability from those undergoing fNIRS or MRI testing.
Time frame: Baseline to 4 months
Feasibility of collecting psychological data
Feasibility will be assessed by focusing on data completeness of validated mental health measures to include GHQ, GAD, PHQ-9.
Time frame: Baseline to 4 months
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 11 months is below that.
Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.